Table 1.
Clinical characteristics and laboratory data of four HIV-infected patients at admission
| Parameters | Case 1 | Case 2 | Case 3 | Case 4 |
|---|---|---|---|---|
| Age (y) | 48 | 53 | 22 | 30 |
| Sex | M | F | M | M |
| ART regimens | TDF + 3TC + DTG | TDF + 3TC + DTG | No ART | TDF + 3TC + EFV |
| ART duration | 1 month | 2 months | None | 5 years |
| Complication | Syphilis | Not found | Not found | Syphilis |
| Hb (g/L) | 15 | 20 | 35 | 69 |
| RCC (×1012/L) | 1.06 | 1.38 | 1.52 | 1.12 |
| MCV (fL) | 98 | 99 | 96 | 103 |
| Ret (%) | 0.20 | 0.22 | 0.28 | 0.21 |
| WBC (×109/L) | 5.45 | 4.77 | 3.07 | 4.57 |
| LYM (×109/L) | 1.91 | 0.62 | 0.68 | 1.68 |
| PLT (×109/L) | 459 | 508 | 315 | 363 |
| CD4 (cells/μL) | 68 | 46 | 24 | 86 |
| HIV RNA (copies/mL) | <20 | 206 | 492000 | <20 |
| B19V DNA | + | + | + | + |
| B19V IgM | N/A | − | − | − |
| B19V IgG | N/A | − | − | − |
| EB DNA (copies/mL) | − | − | − | − |
| CMV DNA (copies/mL) | − | − | − | − |
+: Positive; −: Negative; 3TC: Lamivudine; ART: Antiretroviral therapy; B19V: Parvovirus B19 virus; CD4: CD4 T-cell; CMV: Cytomegalovirus; DTG: Dolutegravir; EB: Epstein-Barr virus; EFV: Efavirenz; F: Female; Hb: Hemoglobin; HIV: Human immunodeficiency virus; LYM: Lymphocytes; M: Male; MCV: Mean cell volume; N/A: Not available; PLT: Platelets; RCC: Red cell count; Ret: Reticulocyte percentage; TDF: Tenofovir disoproxil; WBC: White blood cells.